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a  b  s  t  r  a  c  t
Idiopathic  pulmonary  ﬁbrosis  (IPF) is  characterized  by aberrant  deposition  of  extracellular  matrix  (ECM)
constituents,  including  glycosaminoglycans  (GAGs),  that  may  play a role  in remodelling  processes  by
inﬂuencing  critical  mediators  such  as  growth  factors.  We  hypothesize  that  GAGs  may  be  altered  in  IPF  and
that this  contribute  to create  a pro-ﬁbrotic  environment.  The  aim of  this  study  was  therefore  to examine
the  ﬁne  structure  of  heparan  sulfate  (HS),  chondroitin/dermatan  sulfate  (CS/DS)  and  hyaluronan  (HA)  in
lung samples  from  IPF  patients  and  from  control  subjects.  GAGs  in  lung  samples  from  severe  IPF  patients
and  donor  lungs  were  analyzed  with  HPLC.  HS  was  assessed  by  immunohistochemistry  and  collagen
was  quantiﬁed  as  hydroxyproline  content.  The  total  amount  of  HS,  CS/DS  and  HA  was  increased  in IPF
lungs  but  there  was  no signiﬁcant  difference  in the  total  collagen  content.  We  found  a  relative  increase  in
total sulfation  of HS  due to  increment  of 2-O,  6-O  and  N-sulfation  and  a  higher  proportion  of  sulfation  in
CS/DS.  Highly  sulfated  HS was  located  in the  border  zone  between  denser  areas  and  more  normal  looking
alveolar  parenchyma  in  basement  membranes  of  blood  vessels  and airways,  that  were  immuno-positive
for  perlecan,  as well  as on the  cell  surface  of  spindle-shaped  cells  in  the  alveolar  interstitium.  These
ﬁndings  show  for the ﬁrst time  that  both  the  amount  and  structure  of  glycosaminoglycans  are  altered  in
IPF. These  changes  may  contribute  to the  tissue  remodelling  in  IPF  by altering  growth  factor  retention
and  activity,  creating  a pro-ﬁbrotic  ECM  landscape.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is characterized by extensive
tissue remodelling and aberrant deposition of extracellular matrix
Abbreviations: IPF, idiopathic pulmonary ﬁbrosis; ECM, extracellular matrix;
GAG, glycosaminoglycan; HS, heparan sulfate; CS, chondroitin sulfate; DS, dermatan
sulfate; HA, hyaluronan; UA, uronic acid; GlcA, glucuronic acid; IdoA, iduronic acid;
GalNAc, N-acetyl-d-galactosamine; GlcNAc, N-acetyl glucosamine; FGF, ﬁbroblast
growth factor; VEGF, vascular endothelial growth factor; PDGF, platelet-derived
growth factor; TGF-beta, tumour growth factor-beta; FBS, fetal bovine serum; AMAC,
2-aminoacridone; BSA, bovine serum albumin; FEV1, forced expiratory volume in
1  s; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity for
carbon monoxide; RP-HPLC, reversed-phase high pressure liquid chromatography;
MS,  mass spectrometry; qPCR, quantitative polymerase chain reaction.
∗ Correspondence to: BMC-C12, Klinikgatan 28, S-22184 Lund, Sweden.
E-mail address: oskar.hallgren@med.lu.se (O. Hallgren).
(ECM) constituents including collagens, glycoproteins and proteo-
glycans resulting in stiffer and less compliant tissue that reduces
lung function (Bjoraker et al., 1998). Proteoglycans play important
roles in the ECM inﬂuencing viscoelastic properties, cell differenti-
ation and morphogenesis (Souza-Fernandes et al., 2006). Many of
these functions are however properties of covalently attached gly-
cosaminoglycan (GAG) side chains, but these have paradoxically
not been fully assessed in IPF. GAGs comprise chondroitin sulfate
(CS), dermatan sulfate (DS), heparan sulfate (HS), keratan sulfate
(KS) and hyaluronic acid (HA). The polymers are highly negative
due to carboxylate and sulfate groups that mediate binding of a
range of proteins such as growth factors and cytokines (Mizumoto
et al., 2013; Xu and Esko, 2014). These interactions are not only a
matter of charge but also of the position of sulfate groups that cre-
ates binding motifs in the polymer chain. HA, the most abundant
non-sulfated GAG in the lung, regulates the ﬂuid balance in the
http://dx.doi.org/10.1016/j.biocel.2016.12.005
1357-2725/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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Fig. 1. Location and histological appearance of donor and IPF lung samples.
Tissue pieces were obtained from lungs of donors and IPF patients. A. From donor lungs distal tissue samples were obtained from locations close to the pleura. B. From IPF
patients distal tissue samples were obtained from two locations; samples named “IPF dense” were obtained from locations close to the pleura with high tissue density and
low  compliance, samples named “IPF less dense” were obtained from less dense areas some distance from the pleura with more normal compliance. All pleura and visible
larger  airways and vessels were avoided in the sampling. C–H representative eosin & haematoxylin staining of tissue pieces: C and D from donor lungs, E and F from less
dense areas of IPF lungs and G and H dense areas of IPF lungs. Scale bars = 50 m.
interstitium by its ability to bind and retain water in macromolec-
ular aggregates together with CS-proteoglycans (Allegra et al.,
2012; Wight and Hascall, 1983). The CS/DS proteoglycans versican,
decorin and CD44 have been reported to increase in IPF, but less
is known about their GAG moiety (Bensadoun et al., 1996; Buckley
et al., 2011; Venkatesan et al., 2011). CS/DS chains are composed
of repeating disaccharides of alternating uronic acid (UA), which
can be either be d-glucuronic acid (GlcA) or l-iduronic acid (IdoA),
and N-acetyl-d-galactosamine (GalNAc), that may  be sulfated at
the C-2 position of GlcA/IdoA and/or at the C4 and C6 position of
GalNAc. The UA in CS is GlcA while in DS a variable number of GlcA
residues become epimerized at C-5 to yield IdoA (Malmstrom et al.,
2012; Thelin et al., 2013). HS-proteoglycans are also upregulated
in IPF and have been suggested to contribute to tissue remod-
elling and morphogenesis (Jiang et al., 2010; Kliment et al., 2009;
Ruiz et al., 2012). These effects may  be due to the ability of HS
side chains to inﬂuence retention and activity of critical media-
tors including growth factors. HS is for example involved in the
coordination of ligand-receptor binding of ﬁbroblast growth factor
(FGF), vascular endothelial growth factor (VEGF), platelet-derived
growth factor (PDGF) and tumour growth factor-beta (TGF-)  that
all have been shown to be involved in tissue remodelling processes
active in IPF (Abramsson et al., 2007; Takashima et al., 2016; Xu
and Esko, 2014). These growth factors are, in addition, targets for
Nintedanib and Pirfenidone, the only drugs that have been demon-
strated to have clinical efﬁcacy in IPF patients (Jones et al., 2013;
Richeldi et al., 2014). HS contains repeating units of UA linked to N-
acetyl glucosamine (GlcNAc). During the synthesis in Golgi, the HS
chain becomes modiﬁed in which GlcNAc residues may  become N-
deacetylated and N-sulfated, GlcA may  be epimerized at C5 to yield
IdoA, sulfate groups may  be added at C2 on the uronic acid residue
and the GlcNAc may be sulfated at C6 and more rarely at C3 (Esko
and Lindahl, 2001; Xu and Esko, 2014). The modiﬁcations do not go
to completion which gives rise to extremely variable structures.
Taken together, the dramatic tissue re-organisation in IPF is
accompanied by increased deposition of proteoglycans. However,
many of the most important functions of proteoglycans, such as
to regulate growth factor binding and activity, reside in the GAG
moiety and these structures have not been fully examined in IPF.
We  hypothesized that GAGs may  be involved in this process and
the aim of this study was  therefore to examine the ﬁne structure
of glycosaminoglycans in tissue from dense and less dense areas of
the lungs from patients with IPF in comparison with samples from
donor lungs.
2. Material methods
2.1. Study subjects
2.1.1. Patients
Patients (n = 10) with severe IPF who were undergoing lung
transplantation at the Sahlgrenska University hospital in Gothen-
burg between 2014 and 2015 were included in the study. The
diagnosis of IPF was veriﬁed by histological examination of the
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explanted lungs. The patients had stopped smoking at least 6
months before the lung transplantation. Written consent was
obtained from all subjects before being included in the study.
2.1.2. Control subjects
Lung explants from healthy organ donors (n = 7) with no history
of lung disease were included. Lungs were to be used for transplan-
tation but could instead be included in this study as no matched
recipient could be identiﬁed. In these cases, written consent was
obtained from their closest relatives. The study was approved by
the Swedish Research Ethical Committee in Lund (FEK 91/2006)
and in Gothenburg (FEK675-12/2012).
2.2. Tissue dissection
After crude dissection tissue pieces from distal lungs were kept
in Dulbecco’s MEM  supplemented with 10% FBS, Gentamycin and
Penicillin-Streptomycin (all from Gibco BRL, Paisley, UK) on ice
until further dissection. From IPF patients, tissue pieces were taken
from locations just underneath the pleura with low compliance
and were denoted “IPF dense”. In parallel, tissue pieces were taken
at some distance from the pleura from less dense tissue areas, as
exempliﬁed in Fig. 1, and named “IPF less dense”. From donor lungs,
samples were taken from just below the pleura. Visible airways and
vessels and pleura were systematically avoided. All samples were
then stored in −80 ◦C until further analysis.
2.3. Glycosaminoglycan isolation and digestion
A minimum of two separate tissue pieces was analysed from
each individual and location. The method to isolate and digest
GAG disaccharides has previously been developed in our labora-
tory (Stachtea et al., 2015). All tissue samples were ﬁrst lyophilized
and weighed. Approximately 2 mg  tissue (dry weight) was used
from each tissue sample. Proteins were degraded by an overnight
incubation at 55 ◦C with 200 g/ml pronase (Pronase E, Sigma-
Aldrich, St. Louis, MO,  USA) in 50 mm Tris/HCl, pH 8, 1 mM CaCl2,
and 1% Triton X-100. After heat-inactivation of the protease, MgCl2
was added to a ﬁnal concentration of 2 mM and benzonase (Ben-
zonase
®
Nuclease, Sigma-Aldrich, St. Louis, MO,  USA) was added to
a ﬁnal 20 Sigma units/ml and incubated for 2 h at 37 ◦C. Benzonase
was heat-inactivated, NaCl was added to a ﬁnal concentration of
0.1 M,  and GAGs were puriﬁed on an anion spin column (Viva-
pure Q mini H, Sigma-Aldrich, St. Louis, MO,  USA). The GAGs were
washed ×5 with 20 mM NaAc pH 5.5, 0.2 M NaCl buffer, and eluted
with 20 mM NaAc pH 5.5, 2 M NaCl buffer. Samples were desalted
using spin columns with a cut-off size of 3 kDa Amion
®
Ultra 0.5
centrifugal ﬁlter device, Millipore, Billerica, MA,  USA by repeated
addition of water. Sample amounts that corresponded to 0.3 mg
of the initial dry tissue were used for each digestion. To gener-
ate disaccharides from chondroitin sulfate, dermatan sulfate and
hyaluronic acid, GAGs were subjected to chondroitinase ABC degra-
dation, overnight at 37 ◦C in 20 l 50 mM NH4OAc and 0.1 mg/ml
BSA, containing 10 mU  chondroitinase ABC (Chondroitin ABC Lyase,
C3667, Sigma-Aldrich, St. Louis, MO,  USA). The samples were boiled
and the supernatant was dried. As the eliminase chondroitinase
ABC leaves a double bond C4 = C5, the C5 epimeric conﬁguration in
the native sugar is lost, therefore it cannot be determined whether
the resulting disaccharides originally contained IdoA (dermatan
sulfate) or GlcA (chondroitin sulfate). Therefore, all chondroitinase
ABC-generated disaccharides are named CS/DS. To degrade HS, the
samples were incubated overnight at 37 ◦C with a mixture of hep-
arinase I, II and III (10 mU of each; overexpressed in E. Coli, a kind
gift from Jian Liu, University of North Carolina at Chapel Hill) in
buffer 20 mM HEPES, 50 mM NaCl, 4 mM CaCl2, pH 7.
2.4. Glycosaminoglycan disaccharide analysis
Disaccharide analysis was performed as previously described
(Stachtea et al., 2015). Brieﬂy, ﬂuorophore-labelling of the resulting
disaccharides was  performed by adding 10 l of 20 mM re-puriﬁed
2-aminoacridone (AMAC) (Sigma-Aldrich, St Louis, MS,  USA) to
lyophilized samples, followed by a 20 min  incubation at room
temperature before the addition of 10 l of 1 M NaBH3CN and
incubation at 45 ◦C for 16 h. AMAC-labelled disaccharides were
analyzed with HPLC-ﬂuorescence on a X-Bridge BEH Shield RP18
(2.1 × 100 mm,  2.5 m)  column connected to a Thermo Scientiﬁc
UltiMate 3000 Quaternary Analytical system with an FLD-3400RS
ﬂuorescence detector (excitation  = 428 and emission  = 525) set
at 30 ◦C. 20 l samples were diluted to 100 l in running buffer (98%
A: NH4OAc, 60 mM,  pH 5.6, and 2% B: MeCN) and 2 l were injected
onto the column. Disaccharides were separated using a 39 min
gradient run at 0.35 ml/min (0–1 min: 98% A, 1–3 min: 98–96%
A, 3–26 min: 96–85% A, 26–28 min: 85–10% A, 28–32 min: 10% A,
32–34 min: 10–98% A, 34–39 min: 98% A). Quantiﬁcation was done
by comparison to known weight of standard disaccharides (Iduron,
UK) mock-treated in the same buffers and enzymes as the samples
in each series of runs.
2.5. Determination of hydroxyproline
A commercial kit was used to analyse the hydroxyproline
content (MAK008, Hydroxyproline assay kit, Sigma-Aldrich, Saint-
Louis, MO,  US). All samples were analysed in duplicate according
to the manufacturer’s instructions. From each subject and loca-
tion, a minimum of two pieces were analysed. Intact tissue was
lyophilized and weighed and samples were hydrolysed in 6 M HCl
at 120 ◦C for 3 h. Tissue homogenates were treated with activated
charcoal to reduce soot particles that could inﬂuence the colori-
metric reaction. The hydroxyproline content in the samples was
determined by comparison to a standard curve.
2.6. Sequential extraction of collagen
The method has been previously described (Kalamajski et al.,
2014). Brieﬂy, collagen was sequentially extracted in 0.5 M acetic
acid followed by 0.5 M acetic acid containing 1 mg/ml pepsin acid
at 4 ◦C for 24 h for each step. Supernatants were collected by cen-
trifugation at 14000 × g for 30 min, and pellets were used in the next
step. In order to further separate ﬁbrillar collagens from other types
supernatants were precipitated in 0.9 M NaCl, pH 2.5 overnight at
4 ◦C on a shaker. After centrifugation at 14000 x g for 10 min. the
pellets were washed in 99% Ethanol, 50 mM NaAc at −20 ◦C for 1 h.
The pellets were collected by centrifugation at 14000 × g for 30 min.
The hydroxyproline content was measured as described above in
all supernatants and pellets.
2.7. Mass spectrometry
HAC-pepsin digested collagens were separated on 7% Tris-
Acetate gels and bands were visualized by SimplyBlue SafeStain
(both from Invitrogen, Carlsbad, CA, USA). In-gel digestion of indi-
vidual protein bands was performed using standard protocols
described in (Malmstrom et al., 2016). LC–MS/MS measurements
of digested peptides were acquired on a Q Exactive Plus mass
spectrometer (Thermo Fisher Scientiﬁc). Peptide separation was
carried out by an EASY-nLC 1000 liquid chromatography sys-
tem (Thermo Fisher Scientiﬁc) using an Acclaim PepMap
®
100
(75 M × 2 cm nanoViper C18, 3 m,  100 Å) pre-column (Thermo
Fisher Scientiﬁc), followed by an EASY-Spray (75 m x 25 cm)  sep-
aration column. LC and MS  settings are described in (Malmstrom
et al., 2016). Brieﬂy a 60 min  linear gradient (5–30% over 60 min)
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of acetonitrile in aqueous 0.1% formic acid was  used at a ﬂow
rate of 300 nl/min. For each full MS  scan (resolution 70,000 at
200 m/z, mass range 400–1600 m/z) the 15 most abundant ions
(TOP15) were selected for fragmentation (resolution 17,500 at
200 m/z). The resulting mass spectra were searched using the
Trans-Proteomic Pipeline (TPP, version 4.7) (Deutsch et al., 2010)
against the unreviewed Human UniProt FASTA database (version
April 2015). Cysteine carbamidometylation was set as ﬁxed pep-
tide modiﬁcation and methionine oxidation and hydroxylation of
proline were set as variable peptide modiﬁcations. A precursor ion
mass tolerance of 20 ppm and a fragment ion mass error tolerance
of 50 ppm were used. The false discovery rate was set to 1%.
2.8. RNA isolation, cDNA preparation and real-time quantitative
PCR analysis
Tissue samples from IPF patients and donor lungs were har-
vested in RNAlater (Qiagen, Hilden, Germany) and stored in
−70 ◦C until further processing. Total RNA was  isolated using
the mini RNeasy Mini Kit from (Qiagen, cat. No. 74104). For
preparation of cDNA, the Quantitect Reverse Transcription Kit
(Qiagen, cat. No. 205311) was used. For the qPCR, cDNA prepa-
rations were mixed with Quantitect SYBR Green (Qiagen, cat. No.
204143) along with speciﬁc primers from Qiagen, N-Deacetylase/N-
Sulfotransferase 1, NDST1, (cat. No. QT01002638), Deacetylase/N-
Sulfotransferase 2, NDST2, (cat. No. QT00030520), heparan sulfate
6-O-sulfotransferase 1, HS6ST1, (cat. No. QT00078547), heparan
sulfate 6-O-sulfotransferase 2, HS6ST2, (cat. No. QT01028370), hep-
aran sulfate 2-O-sulfotransferase 1, HS2ST1, (cat. No. QT00010073),
18S ribosomal RNA, RRN18S, (cat. No. QT00199367), and analyzed
on a Mx3005P qPCR system (Stratagene, La Jolla, CA, USA) with stan-
dard cycling parameters to perform thermo-cycling and real-time
detection of PCR products.
2.9. Immunohistochemistry
8 m cryosections of lung tissue from healthy donors and IPF
patients were air-dried and rehydrated. For A04B08V, endogenous
peroxidase activity was blocked with 1% hydrogen peroxide in
methanol for 30 min, followed by blocking of endogenous biotin
using a streptavidin/biotin blocking kit according to the manu-
facturer’s instructions (Vector Laboratories, Burlingame, CA, USA).
After blocking with 1% BSA and 0.05% Tween-20 for 20 min, tissue
sections were incubated for 1 h at room temperature with a 1:10
dilution of the phage-display antibody fragment A04B08V which
had been demonstrated to preferentially recognize 2-O-, 6-O- and
N-sulfated HS polymers (Kurup et al., 2007). This step was  followed
by incubation with a 1:800 dilution of mouse anti-VSV-G antibody
(clone P5D4) (Sigma-Aldrich, St. Louis, MO,  USA) at room temper-
ature for 1 h. Sections were then ﬁxed in 4% formalin for 30 min
and incubated with a biotinylated goat anti-mouse IgG antibody
(Vector Laboratories, Burlingame, CA, USA) at room temperature for
1 h. Following incubation with the avidin/biotin-based peroxidase
complex Vectastain Elite ABC (Vector Laboratories, Burlingame,
CA, USA), sections were developed with the peroxidase substrate
NovaRED (Vector Laboratories, Burlingame, CA, USA), all according
to the manufacturer’s instructions. Sections were counterstained
with Mayer’s haematoxylin (Sigma-Aldrich, St. Louis, MO,  USA),
dehydrated, mounted with Pertex mounting medium (Histolab,
Gothenburg, Sweden) and photographed using an Olympus BX50F
microscope (Olympus, Tokyo, Japan) equipped with an Olympus
DP80 camera (Olympus, Tokyo, Japan). To verify the speciﬁcity of
the stainings, tissue sections were pre-treated overnight at 37 ◦C
with a combination of heparinase I, heparinase II and heparinase
III, each at 0.1 IU/ml, in an enzyme buffer made up of HEPES (20 mM)
NaCl (50 mM),  CaCl2 (4 mM),  and BSA (0.01%) (pH 7.2). For the
Table 1
Control subjects and IPF patients in the study.
Characteristics Controls (range) IPF (range)
No. 7 10
Age (range) 51 (39–65) 57 (45–69)
Ex-smokers/non-smokers 1/6 8/2
Gender, M/F  4/3 4/6
Lung function
FEV1 m 1.6 (0.8–2.4)
FEV1 (% predicted) m 56 (30–90)
FVC m 2.0 (0.9–3.3)
FVC  (% predicted) m 56 (31–106)
TLC m 3.1 (1.5–4.7)b
TLC (% predicted) m 49 (31–96)a
DLCO m 2.1 (1.3–2.8)b
DLCO (% predicted) m 27 (16–47)a
a Only values from nine patients.
b Only values from eight patients. m denotes that data is missing.
Heparan sulfate and Perlecan stainings, sections were ﬁxed imme-
diately after air-drying and incubated with the primary antibody at
10 g/ml (anti-Heparan Sulfate, 10E4 epitope, Amsbio, Abingdon,
UK) or 0.5 g/ml (anti-Perlecan, 7B5 clone, ThermoFisher Scien-
tiﬁc, Rockford, IL, USA) for 2 h at room temperature, followed by
incubation with the biotinylated goat anti-mouse IgG antibody
and development according to procedures described above. The
speciﬁcity of the anti-Heparan Sulfate antibody was veriﬁed by a
pre-treatment overnight at 37 ◦C with a mixture of heparinases III
as described for A04B08 V and for anti-Perlecan by use of a mouse
IgG1 isotype control.
2.10. Statistics
Data are expressed as mean ± SD. Statistical differences between
groups were determined by the Mann-Whitney U test. In addition,
the Wilcoxon signed rank test was used to determine differences
within patients. Differences were considered signiﬁcant at p < 0.05.
All analyses were performed using GraphPad Prism software ver-
sion 6.0f (GraphPad Software, San Diego, CA).
3. Results
3.1. Study subjects and dissection
The mean age was 51 years (range 39–65) in controls and 57
years (range 45–69) in the IPF group. Among the IPF patients 8 out of
10 were ex-smokers whereas 1 out of 7 of the controls had a history
of smoking. The mean FEV1 was  56% of predicted (range 30–90%)
and the mean FVC was  56% of predicted (range 31–106%) in the IPF
patients. DLCO was  27% of predicted (range 22–47%) in IPF patients.
Demographics of IPF patients and control subjects are shown in
Table 1. The diagnosis of IPF patients was  veriﬁed by histological
examination by an experienced pathologist of the explanted lungs.
Since the control tissue came from donor lungs that ultimately were
not used for transplantation we  have no lung function parameters
from these individuals. From IPF patients, lung pieces were sampled
from two  separate locations: from (1) dense tissue areas just below
the pleura and from (2) less dense areas more distant from the
pleura, while from control subjects only sub-pleural samples were
taken (Fig. 1)
3.2. Hydroxyproline determination in lung tissue
To characterize the sampled tissue, hydroxyproline was mea-
sured as an indirect measure of the total collagen content. There
was a trend that the hydroxyproline content was  higher in both less
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Fig. 2. Hydroxyproline measurement in lung samples.
A. Total hydroxyproline content normalized to the dry weight of the tissue. B.
Collagen was sequentially extracted by acetic acid and pepsin digestion and the
hydroxyproline content was measured in each fraction. The extraction by acetic
acid  gave values below the detection limit and was  therefore combined with pepsin
extraction. Values show the percentage of hydroxyproline found in one fraction in
relation to the total content in a sample. A minimum of two separate tissue pieces
was  analysed from each subject and location (n = 7 for control subjects and n = 10
for  IPF patients). +P < 0.05 using Wilcoxon test.
dense and dense areas from IPF patients compared to control lungs
but these differences were not statistically signiﬁcant (Fig. 2A).
The hydroxyproline values corresponded to 95 g collagen/mg
tissue in controls and 128 and 118 g collagen/mg tissue in less
dense and dense areas of IPF lungs, respectively (Table 2). Moreover,
in adult human lung the majority of ﬁbrillar collagens are heavily
cross-linked and the turnover rate is relatively low. In active remod-
elling processes, such as in IPF, a higher degree of ECM turnover
can be expected and this might result in elevated levels of colla-
gen that are not fully cross-linked. To try this hypothesis, collagen
was serially extracted from the lung samples and hydroxyproline
was measured in all steps. Acid treatment causes a release of col-
lagens with crosslinks mainly in the helix domain. However, this
treatment resulted in levels that were below the detection limit of
the hydroxyproline measurement in all samples (data not shown).
In contrast, 3–8% of the total pool of collagens were extracted by
Fig. 3. Glycosaminoglycans are increased in IPF lungs but do not differ between
dense and less dense IPF samples.
GAGs were digested with chondroitinase ABC or heparinase I, II and III to generate
disaccharides that were separated with HPLC and compared to disaccharide stan-
dards as shown in Figs. S1 and S2 . Total GAG is the sum of CS/DS, HA and HS.
Chondroitin sulfate/dermatan sulfate (CS/DS) is the sum of the following disaccha-
rides: UA-GalNAc (0), UA-GalNac-4S (A), UA-GalNac-6S (C), UA-2S-GalNac-4S (B),
UA-2S-GalNac-6S (D), UA-GalNac-4S-6S (E) as shown in Fig. S1. heparan sulfate (HS)
is  the sum of the following disaccharides: UA-GlcNAc, UA-2S-GlcNAc, UA-GlcNAc-
6S, UA-GlcNS, UA-2S-GlcNAc-6S, UA-2S-GlcNS, UA-GlcNS-6S and UA-2S-GlcNS-6S
as  shown in Fig. S2. A minimum of two separate tissue pieces was analysed from each
subject and location (n = 7 for control subjects and n = 10 for IPF patients). **P < 0.01,
***P  < 0.001 using Mann-Whitney test.
the addition of pepsin that releases collagens with cross-links also
in the telopeptide domain (Fig. 2b). The absolute majority of colla-
gens in this fraction were ﬁbrillar as they precipitated in 0.9 M NaCl
at pH 2.5. The predominating collagens were the ﬁbrillar type-I, III
and V collagens but also type-IV and VI collagen (Table S1). There
was a signiﬁcant increase in the relative level of pepsin-extracted
collagens in less dense areas of IPF lungs compared to dense areas.
However, the majority of collagens were acid and pepsin-resistant
suggesting that they were further cross-linked (Fig. 2b).
3.3. Increased levels of all GAGs in IPF lungs
By isolating and digesting GAGs with speciﬁc enzymes we  could
quantitate the total pool of CS/DS, HA, HS disaccharides with RP-
HPLC (Figs. 3 , S1 and S2, values for individual patients are shown
in Fig. S3). With this protocol we  were able to analyse the six most
common CS/DS disaccharides, HA and the eight most common HS
disaccharides with base-line separation. There was a three-fold
increase in the total pool of GAGs as well as in CS/DS, HA and HS in
both less dense and dense areas in IPF lungs. This corresponded to
1.3 g of total GAG/mg tissue in controls and 3.4 and 3.6 g total
GAG/mg tissue in less dense and dense areas of IPF lungs, respec-
tively (Table 2) suggesting that GAGs are relatively more increased
than collagen in IPF.
3.4. Increased levels of CS/DS in IPF lungs
Individual CS/DS disaccharides were analysed by HPLC (Figs. 4
and S1). All the investigated disaccharides were increased both in
less dense and dense areas of IPF lungs compared to donor lungs
(Fig. 4A). Accordingly, the general increase in all CS/DS disaccha-
rides in IPF resulted in elevated levels of 4-O, 6-O, 2-O sulfated
disaccharides and thereby in the total pool of sulfated CS/DS GAGs
(Fig. 4B). To examine if there were also alterations in the relative
abundance of CS/DS disaccharides the disaccharide composition
was calculated (Fig. 4C and D). In dense areas in IPF lungs the
relative degree of sulfation was increased and, as a consequence,
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Table  2
Absolute levels of collagen and GAGs.
Control (range) IPF less dense (range) IPF dense (range)
Collagena 95 (60–134) 128 (74–194) 118 (79–181)
Total  GAGb 1.3 (0.8–1.9) 3.4 (1.3–4.8) 3.6 (1.8–6.0)
CS/DSb 0.6 (0.3–1.0) 1.5 (0.5–2.3) 1.6 (0.9–2.3)
HAb 0.3 (0.1–0.4) 0.9 (0.2–1.3) 1.0 (0.6–1.7)
HSb 0.4 (0.3–0.5) 0.9 (0.5–1.2) 1.0 (0.3–2.1)
a Mean value of the total collagen content in tissue samples (g collagen/mg dry tissue). The collagen concentration was calculated as (measured hydroxyproline ×7.4) as
has  been described (Neuman and Logan, 1950).
b The mean of individual GAGs or the sum of all measured GAGs (g GAG/mg dry tissue).
Fig. 4. CS/DS is increased in both dense and less dense areas in IPF lungs.
GAGs were digested with chondroitinase ABC to generate disaccharides that were separated with HPLC and compared to disaccharide standards as shown in Fig. S1. A. Absolute
quantiﬁcation of CS/DS disaccharides. B. Summary of CS/DS disaccharides with speciﬁc sulfation, [Total CS/DS]: the sum of all CS/DS, [Sulfated CS/DS]: the sum of sulfated
disaccharides i.e. UA-GalNac-4S (A), UA-GalNac-6S (C), UA-2S-GalNac-4S (B), UA-2S-GalNac-6S (D), UA-GalNac-4S-6S (E), [4-O-S]: the sum of 4-O sulfated disaccharides
i.e.,  UA-GalNac-4S (A), UA-2S-GalNac-4S (B), UA-GalNac-4S-6S (E), [6-O-S]: the sum of 6-O sulfated disaccharides i.e. UA-GalNac-6S (C), UA-2S-GalNac-6S (D), UA-GalNac-
4S-6S  (E), [2-O-S]: the sum of 2-O sulfated disaccharides i.e. UA-2S-GalNac-6S (D), 2S-GalNac-4S (B), [non-sulfate]: non-sulfated disaccharides i.e. UA-GalNAc (0) C. CS/DS
disaccharide composition presented as mole% of total. D. Relative abundance of the different sulphation patterns of CS/DS disaccharides presented as the mole% of total. A
minimum of two  separate tissue pieces was analysed from each subject and location (control subjects n = 7 and n = 10 for IPF patients). *P < 0.05, **P < 0.01 and ***P < 0.001
using  Mann-Whitney test.
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Fig. 5. Increased sulfation in HS from IPF lungs.
GAGs were digested with Heparinase I, II and III to generate HS disaccharides that were separated with HPLC and compared to disaccharide standards as shown in Fig. S2.
A.  Absolute quantiﬁcation of HS disaccharides. B. Summary of HS disaccharides with speciﬁc sulfation patterns. [Total HS]: the sum of all HS, [Sulfated HS]: the sum of all
sulfated HS disaccharides i.e. UA-2S-GlcNAc + UA-GlcNAc-6S + UA-2S-GlcNAc-6S + UA-GlcNS + UA-2S-GlcNS + UA-GlcNS-6S + UA-2S-GlcNS-6S, [N-S]: the sum of N-sulfated HS
disaccharides i.e., UA-GlcNS + UA-2S-GlcNS + UA-GlcNS-6S + UA-2S-GlcNS-6S [2-O-S]: the sum of all 2-O sulfated HS  disaccharides i.e. UA-2S-GlcNAc + UA-2S-GlcNAc-6S + UA-
2S-GlcNS + UA-2S-GlcNS-6S, [6-O-S]: the sum of all 6-O sulfated HS disaccharides i.e. UA-GlcNAc-6S + UA-2S-GlcNAc-6S + UA-GlcNS-6S + UA-2S-GlcNS-6S, [non-sulfate]: the
non-sulfated disaccharides i.e. UA-GlcNAc. C. HS disaccharide composition presented as mole% of total. D. Relative abundance of the different sulphation patterns of HS
disaccharides presented as the mole% of total. A minimum of two separate tissue pieces was analysed from each subject and location (n = 7 for control subjects and n = 10 for
IPF  patients). *P < 0.05, **P  < 0.01 and ***P < 0.001 using Mann-Whitney test, +P < 0.05, using Wilcoxon test.
non-sulfated disaccharides were decreased compared to donor
lungs. This data suggests that there is a general increase in CS/DS
in dense and less dense areas in IPF lungs and, in addition, in dense
tissue areas the relative amount of sulfation is increased.
3.5. Increased levels of HS in IPF lungs
The eight most abundant HS disaccharides found in human tis-
sue was analysed in the lung samples by RP-HPLC (Figs. 5 A and S2).
All disaccharides were signiﬁcantly increased both in less dense
and dense areas in IPF lungs compared to donor lungs (Fig. 5A
and B). This resulted in an increase in the total pool of sulfated
HS disaccharides as well as N-,  2-O and 6-O sulfated HS (Fig. 5B).
The triple-sulfated disaccharide UA-2S-GlcNS-6S was increased
ﬁve-fold and ten-fold in less dense and dense areas of IPF lungs,
respectively and was  thus the most increased disaccharide. Next,
the disaccharide composition was calculated (Fig. 5C and D). In
dense areas of IPF lungs there was  a signiﬁcant increase of UA-2S-
GlcNS-6S, UA-GlcNS-6S and UA-2S-GlcNAc on expense of UA-GlcNS
and UA-GlcNAc that was  decreased compared to donor lungs. UA-
2S-GlcNS-6S was  also increased, while UA-GlcNS was decreased in
less dense tissue areas in IPF. In both less dense and dense areas
in IPF lungs the relative degree of sulfation was increased and, as
a consequence, non-sulfated disaccharides were decreased com-
pared to donor lungs. The increase was  dependent on elevated
levels of N-,  2-O and 6-O sulfation. We  conclude that there was
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Fig. 6. Tissue expression of the enzymes that catalyse the sulfation of HS.
qPCR was  used to examine the expression of the sulfotransferase that are responsi-
ble  for the sulfation of HS in donor and IPF lungs. Fold changes of NDST-1, NDST2,
HS6ST1, HS6ST2 and H2ST1 were normalized to the expression of S18 (control
subjects n = 4 and IPF patients n = 8). *P < 0.05, using Mann-Whitney test.
a general increase in all HS disaccharides in IPF lungs. The disac-
charide composition revealed that HS is more sulfated in both less
dense and dense areas of IPF lungs compared to donors.
3.6. Expression of enzymes that catalyse the sulfation of HS
We  next examined the expression of the sulfotransferases
that are responsible for the sulfation of HS. As we  did not
record a difference in the amount of sulfation of HS between
dense and less dense tissue areas from IPF patients we  only
analysed the tissue expression in less dense tissue sam-
ples. We  examined Deacetylase/N-Sulfotransferase, NDST1, and
Deacetylase/N-Sulfotransferase 2, NDST2, that are responsible for
N-sulfation, Heparan Sulfate 6-O-Sulfotransferase 1, HS6ST1 and
Heparan Sulfate 6-O-Sulfotransferase 2, HS6ST2, that are respon-
sible for 6-O sulfation and Heparan Sulfate 2-O-Sulfotransferase 1,
HS2ST1 responsible for 2-O sulfation. The expression of H6ST2 was
decreased in tissue from IPF patients compared to from donor lungs,
while no other enzymes were altered (Fig. 6).
3.7. Location of highly sulfated HS in IPF lungs
To locate the most increased HS disaccharides, UA-2S-GlcNS-6S
and UA-GlcNS-6S, in IPF lungs, immunohistochemistry was  used
with an antibody fragment, AO4B08, developed by phage display
that preferentially binds N-sulfated octasaccharides with three
consecutive 6-O sulfated disaccharides and an internally located
2-O sulfate group (Kurup et al., 2007). To differentiate positive
staining from background, sequential sections were pre-treated
with a mixture of heparinase I–III that degrade heparan sulfate
and eliminate the epitope. In addition, we used another antibody,
10E4, that prefers HS epitopes that includes N-sulfated glucosamine
residues and thus has a broader HS binding speciﬁcity (van den
Born et al., 2005). As HS is found in basement membranes we  also
included antibodies against perlecan to elucidate a potential core
protein. In donor lungs there was a very limited staining of AO4B08
while 10E4 and perlecan were widely distributed in basement
membranes in airways and blood vessels and in smooth muscle
cells (Fig. 7). In IPF patients, there was a strong signal for AO4B08
in the border zone between dense and less dense tissue areas while
the signal was weaker in areas with dense ﬁbrosis and in normal
looking alveoli (Figs. 8 A and B and S4). The staining for 10E4 and
perlecan were widely distributed throughout the tissue in base-
ment membranes of airways and blood vessels (Figs. 8 C–F and
S4). As a consequence, the three antibodies were located on similar
structures in the border zones, suggesting that perlecan may  be one
core protein that harbours highly sulfated heparan sulfate. This data
show that HS is very abundant in the IPF lung, but highly sulfated
HS is restricted mainly to the border zones that may represent areas
with more active tissue remodelling. Close-ups of the tissue locali-
sation of AO4B08 reveals that it is present on basement membranes
and smooth muscle cells of airways and differently sized blood ves-
sels (Fig. S5). Finally, in a majority of IPF patients, immuno-positive
spindle-shaped elongated cells were found in the border zones (Fig.
S5).
4. Discussion
Our results show that HS, CS/DS and HA are increased in both
less dense and dense areas in lung tissue from patients with severe
IPF compared to donor lungs. The HS disaccharide composition was
altered in IPF with increased proportion of 2-O, 6-O and N-sulfated
disaccharides and there was also an increased degree of sulfation
of CS/DS. Highly sulfated HS was speciﬁcally located in the border
zone between denser areas and more normal looking alveoli. Here
it was located in basement membranes positive for perlecan as well
as on the cell surface of spindle-shaped cells in the alveolar inter-
stitium. As these structures have been implicated in growth factor
retention and activity this may  have impact on the ﬁbrotic process
(Esko and Lindahl, 2001).
In the present study CS/DS, HA and HS were increased 3-fold in
IPF patients and there was  a trend that the total collagen content
was increased in IPF patients compared to control subjects. Sub-
sequently, the GAG to collagen ratio increased from around 1% in
controls to more than 3% in IPF patients (weight/weight). This data
show that the dramatic tissue remodelling in IPF is accompanied by
a higher increase in GAGs than in collagen. Moreover, we  observed
that the HS composition was modiﬁed in IPF as the proportion of N,
2-O and 6-O-sulfated HS disaccharides was  increased compared to
control. Alterations in the HS sulfation landscape have been demon-
strated to inﬂuence growth factor retention and activity (Lensen
et al., 2005). An increase in the proportion of 6-O sulfated disac-
charides and transcripts for HS6ST1 and HS6ST2, the enzymes that
are responsible for this speciﬁc sulfation has been shown in IPF,
and silencing of these gene transcripts in lung ﬁbroblasts resulted
in a lower responsiveness to TGF-ß1 (Lu et al., 2014). In this study
we did not see an increase of the sulfotransferase transcripts, but
mRNA only show a snapshot of what is going on in the tissue and
extracellular HS may  have a slower turnover. Increased proportion
of 6-O sulfated HS has also been shown in chronic renal ﬁbrosis
and was  associated with the ability to mediate FGF-2 signalling
(Alhasan et al., 2014). The role of HS in the formation of ternary
complex between ligands and receptors in FGF  family has been
studied extensively and the binding of FGF-1 and FGF-2 to FGFR-1
and FGFR-2 require N, 2-O and 6-O sulfated HS (MacKenzie et al.,
2015; Powell et al., 2002; Settembre et al., 2008). PDGF has also
been implicated in the pathogenesis of IPF and the retention and
activity in tissue has been demonstrated to be dependent on the
interaction with HS (Abramsson et al., 2007; Homma et al., 1995;
Maeda et al., 1996). For this interaction N-sulfation was required
while it was the overall degree of sulfation rather than the speciﬁc
amount of 2-O and 6-O sulfation that was  important. The altered HS
composition that we  found in IPF may thus suggest that the ECM
landscape in IPF favours growth factor activity and tissue remod-
elling. Moreover, by immunohistochemistry we found that highly
sulfated HS was  speciﬁcally located in the border zone between
dense and less dense areas in basement membranes of blood vessels
and airways. These structures were also positive for the proteo-
glycan perlecan suggesting that this may  be one core protein that
harbours the highly sulfated HS polymers. We  also found highly
sulfated HS on the cell membrane of spindle-shaped ﬁbroblast-
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Fig. 7. Expression and localization of HS and perlecan in donor lungs.
Serial cryosections from representative tissue areas from donor lungs were stained with AO4B08, a phage display-derived antibody fragment, that recognizes highly sulfated
regions  in HS that contain N-,  2-O and 6-O sulfated disaccharides, with 10E4, that are reactive against less sulfated stretches within HS polymers and for the HS-proteoglycan
perlecan. A. Staining for AO4B08. B. Pre-treatment with Heparinase I, II and III decreases the reactivity of AO4B08. C. Staining for 10E4. D. Pre-treatment with Heparinase I, II
and  III eliminates the staining of 10E4. E. Perlecan staining that requires Heparinase pre-treatment. F. Isotype control. Structures that are stained by all three antibodies are
shown indicated by solid arrowheads. Open arrowheads show structures that are positive for 10E4 and perlecan but not AO4B08. Scale bars = 100 m.
like cells in the interstitium in IPF patients. This result conﬁrms
data showing that cell bound HS-proteoglycans, including synde-
cans and glypicans are increased in IPF (Jiang et al., 2010; Kliment
et al., 2009; Ruiz et al., 2012).
We observed an increase in CS/DS in both dense and less dense
areas of IPF lungs. The increase was due to elevated levels of all
observed disaccharides and there was also a difference in the CS/DS
composition with a higher proportion of sulfation. Increased levels
of 4-O and 6-O-sulfated CS/DS disaccharides have been reported
in experimental ﬁbrosis and up-regulation of key enzymes in the
CS/DS biosynthesis has been shown in IPF patients (Venkatesan
et al., 2011). Moreover, elevated mRNA level and tissue staining of
CS/DS proteoglycans including versican, CD44 and decorin has been
shown in lungs from IPF patients (Bensadoun et al., 1996; Buckley
et al., 2011; Venkatesan et al., 2014; Westergren-Thorsson et al.,
2004). Noteworthy, our analysis could not determine the content
of iduronic acid in the CS/DS chains.
In the present study the collagen content in IPF patients tended
to increase compared to control subjects, without reaching statis-
tical signiﬁcance. Although this is consistent with one study the
majority of studies suggest that the total collagen content as well as
the predominating collagen isoforms increase in IPF patients com-
pared to control subjects (Fulmer et al., 1980, 1979; Kirk et al., 1986,
1984; Parra et al., 2006; Raghu et al., 1985; Selman et al., 1986).
However, the increase is sometimes subtle because of the hetero-
geneous distribution of collagen in lung tissue and the patchiness
of ﬁbrotic areas in IPF lungs, that may  introduce sampling errors
(Laurent, 1986). This problem may  be minimized by increasing the
sample size from each individual and to include more patients
which was not possible in the present study. The increased tis-
sue stiffness in IPF may  also be a matter of collagen cross-linking
(Chien et al., 2014; Last et al., 1990; Neuman and Logan, 1950).
We  approached this issue by sequential extraction of collagen. The
majority of collagens were resistant to acid and pepsin extraction
both in IPF patients and control subjects suggesting that ﬁbrillar
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Fig. 8. Highly sulfated HS co-localize with perlecan in the border zone between dense and less dense areas of IPF lungs.
Serial cryosections from IPF lungs were stained with AO4B08, a phage display-derived antibody fragment, that recognizes highly sulfated regions in HS that contain N-,  2-O
and  6-O sulfated disaccharides, with 10E4, that are reactive against less sulfated stretches within HS polymers and for the HS-proteoglycan perlecan. A. Staining for AO4B08.
B.  Pre-treatment with Heparinase I, II and III decreases the reactivity of AO4B08. C. Staining for 10E4. D. Pre-treatment with Heparinase I, II and III eliminates the staining
of  10E4. E. Perlecan staining that requires Heparinase pre-treatment. F. Isotype control. Structures that are stained by all three antibodies are shown indicated by solid
arrowheads. Open arrowheads show structures that are positive for 10E4 and perlecan but not for AO4B08. Scale bars = 200 m.
collagens are heavily cross-linked in adult individuals regardless of
disease as has been shown in other studies (Seyer et al., 1976). How-
ever, as we did not examine pepsin-insensitive collagens that were
further cross-linked the possibility that there may still be alter-
ations cannot be excluded. Our analysis revealed an increase in the
proportion of ﬁbrillar collagens sensitive to pepsin in less dense
compared to dense tissue areas in IPF when using paired analy-
sis. This suggests that there are areas within the IPF lungs with
increased collagen turnover and less cross-linked collagen, as has
previously been shown (Decaris et al., 2014).
One of the major roles of glycosaminoglycans, and HA in par-
ticular, is to regulate ﬂuid content in tissue. Mature tissue has a
lower concentration of water than in early life, but during tissue
repair higher water content is crucial to rebuild the matrix scaf-
fold, which ﬁts well with active tissue remodelling in IPF (Turino
and Cantor, 2003). How this alteration inﬂuences compliance and
tissue stiffness remains to be elucidated. In addition, HA has been
shown to inﬂuence the phenotype and especially the invasiveness
of ﬁbroblast/myoﬁbroblasts. This property is dependent on HA and
its receptor CD44, as the invasive capacity of ﬁbroblasts from IPF
lungs is dependent on expression of HA synthase 2 (Li et al., 2011).
More material than can be achieved by lung biopsies were
needed for the analysis presented in this study, and we therefore
used lung explants from severe IPF patients and donors and could
not examine patients in less advanced disease states. IPF is con-
sidered to be a progressive disease characterized by dense ﬁbrotic
tissue areas that expand over time. With this knowledge we stud-
ied tissue samples from dense or less dense areas of IPF lungs.
The selection of dense and less dense tissue samples was based on
morphology and location in relation to the pleura. There was, how-
ever, a great deal of heterogeneity between and within IPF patients.
Despite this, we  were able to record differences that reﬂect disease
activity suggesting that the division of sample groups still may  be
relevant. Our cohort of IPF patients was  younger than what can be
expected but to our knowledge there are no cases of familiar disease
but we  cannot exclude that possibility. The fact that we only have
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patients that were undergoing lung transplantation may  favour a
younger cohort.
5. Conclusion
In conclusion, our data show for the ﬁrst time, that the aberrant
tissue remodelling in IPF is accompanied by an increased depo-
sition of GAGs. In addition, the ﬁne structure of HS is altered with
increased sulfation, which may  inﬂuence growth factor binding and
activity and thus impact the ﬁbrotic process.
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